Alginate microcapsules for cell encapsulation and, manufacturing method therefor

A technology of alginate and microcapsules, which is applied in the field of surface modified alginate microcapsules, which can solve problems such as melting, weak binding force, and weak physical properties, so as to minimize immune reactions, improve protection, and improve cell survival rate effect

Active Publication Date: 2021-02-02
OPTIPHARM
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, when transplanted in vivo, there may be a problem that due to Ca 2+ in vivo with Na + Exchange or natural diffusion (diffusion), the alginate hydrogel used for the envelope gradually melts in the body
In the case of alginate-dopamine conjugates, they can bind to each other through the oxidation of dopamine, but the binding requires H 2 o 2 The binding force with horseradish peroxidase (HRP) is not strong, and it has a slightly poorer functional limitation such as antiproliferative effect and radical scavenging
In the case of hyaluronic acid-epigallocatechin gallate conjugate, since hyaluronic acid is a substance that can be naturally decomposed in the body, the prepared conjugate can be decomposed in vivo, based on epigallocatechin The reaction speed of the hydrogel bonded with theophyl gallate is slow and the physical properties are not strong, so it is difficult to apply to fine coatings

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Alginate microcapsules for cell encapsulation and, manufacturing method therefor
  • Alginate microcapsules for cell encapsulation and, manufacturing method therefor
  • Alginate microcapsules for cell encapsulation and, manufacturing method therefor

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0082] And, the present invention provides the preparation method of following surface modified microcapsules: comprise: core preparation step (1), prepare calcium alginate microcapsule; Shell preparation step (2), by making calcium alginate microcapsule and epigallocate Theophin gallate dimer reacts to form alginate epigallocatechin gallate dimer cross-linked product on the surface of the above-mentioned calcium alginate microcapsule; and nuclear liquefaction step (3), the calcium alginate The calcium ions are chelated to the epigallocatechin gallate dimer to chelate the calcium ions of calcium alginate, the core is fluid alginate, and the shell is composed of epigallocatechin gallate dimer Cross-linked alginate hydrogel.

[0083] First, calcium alginate microcapsules are prepared.

[0084] Next, the calcium alginate microcapsules and the epigallocatechin gallate dimer were reacted. As a result of the above reaction, the alginate of the calcium alginate hydrogel is cross-li...

Synthetic example 1

[0108] Synthesis example 1. Preparation of epigallocatechin gallate (EGCG) dimer

[0109] 2,2-diethoxyethylamine (2,2-diethoxyethylamine, DA) exists as an aldehyde in an acidic environment. Epigallocatechin was prepared by reacting epigallocatechin gallate (EGCG) with 2,2-diethoxyethylamine under methanesulfonic acid (MSA) to cause aldehyde-mediated polymerization Theophyl gallate dimer.

[0110] Specifically, 3.8 ml of tetrahydrofuran and 7 μl of methanesulfonic acid were mixed in a 10 ml vial, and 2.29 g (5 mmol) of epigallocatechin gallate was added under nitrogen flow in a dark room, followed by stirring for 1 to 2 hours. Next, in a cooled 10 ml vial, 145 μl of 2,2-diethoxyethylamine was added to a mixed solvent of 1 ml of tetrahydrofuran and 0.2 ml of methanesulfonic acid and stirred for 20 to 30 minutes to remove aminoacetaldehyde acetaldehyde. The ethoxy group in diethyl and exposes the aldehyde group. Slowly drip the 2,2-diethoxyethylamine solution from which the et...

Synthetic example 2

[0115] Synthesis Example 2. Preparation of Alginate-Epigallocatechin Gallate Conjugate

[0116] Using the coupling reaction mediated by carbodiimide, the epigallocatechin gallate dimer was bonded to a polymer having a carboxylic acid group by the method of Reaction Formula 2. In the presence of N-hydroxysuccinimide (NHS), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) under acidic conditions (pH4.7), the algal Alginate reacts overnight with epigallocatechin gallate dimer to form an amide bond between the amine group of epigallocatechin gallate and the carboxylic acid of HA to form an amide bond To prepare alginate-epigallocatechin gallate conjugate.

[0117] Reaction 2

[0118]

[0119] Specifically, under dark room conditions, in a 3-necked flask, 202 mg of algal salt and stir. After the alginate was completely dissolved, the inside of the flask was replaced with a nitrogen atmosphere and sealed. After dissolving 89 mg of N-hydroxysuccinimide (0.78 mmol) in 3 ml...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a novel rhamnolipid compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof. A novel rhamnolipid compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof, according to the present invention, inhibits cancer cell growth by exhibiting cytotoxicity in human cancer cell lines, thereby having an excellent preventative ortherapeutic effect especially on the aforementioned cancer.

Description

technical field [0001] The present invention relates to surface-modified alginate microcapsules, its preparation method and its cell envelope method, and in more detail, relates to cell envelopes that can be used to protect cells from the external environment during cell transplantation and improve cell Survivable surface-modified alginate microcapsules, methods for their preparation, and cell envelope methods utilizing them. [0002] The present invention refers to the alginate whose core is fluid, the shell is an alginate hydrogel cross-linked by epigallocatechin gallate dimer, and the surface modified alginate with a core-shell structure Microcapsules, their preparation method, and cell envelope method using the same. Background technique [0003] Due to its excellent biocompatibility and biological inertness, alginate can be used as a biomaterial in various fields such as tissue engineering, cell therapy, and artificial organ manufacturing. [0004] In the treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/50A61K47/36A61K47/54A61K35/39A61P3/10A61L27/38A61L27/20A61L27/54
CPCA61K35/39A61K9/5036A61K47/61A61K47/6925A61K47/6903A61K47/55B01J13/22B01J13/20B01J13/14B01J13/046A61K9/5015A61L27/3687A61L27/3604A61L2300/622A61K9/50A61K31/353C08J7/04C08J2305/04
Inventor 李东玧李在彬崔起明沈周炫朴在庆
Owner OPTIPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap